NorthRock Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

NorthRock Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-803	Closed	-$65.1K	–	952
2025 Q1	$65.1K	Buy	803 +100	+14%	+$8.94K	﹤0.01%	664
2024 Q4	$63.3K	Sell	703 -155	-18%	-$15K	﹤0.01%	641
2024 Q3	$84.7K	Buy	858 +10	+1%	+$983	﹤0.01%	667
2024 Q2	$78.6K	Sell	848 -56	-6%	-$5.02K	﹤0.01%	636
2024 Q1	$85.8K	Buy	904 +749	+483%	+$69.5K	﹤0.01%	634
2023 Q4	$13.8K	Buy	+155	New	+$11.5K	﹤0.01%	671

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

NorthRock Partners's XBI Position: Q2 2025 in Review

NorthRock Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2025, closing a stake of 803 shares — an estimated $65.1K sold.

NorthRock Partners first reported a position in XBI in Q4 2023 and held it in 6 quarters. The position peaked at $85.8K in Q1 2024. 625 funds tracked by Wall St. Rank hold XBI as of Q2 2025.

NorthRock Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2025 after selling out during the quarter.
NorthRock Partners sold 803 State Street SPDR S&P Biotech ETF shares in Q2 2025, an estimated $65.1K.
NorthRock Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and held it in 6 quarters.
NorthRock Partners's State Street SPDR S&P Biotech ETF position peaked at $85.8K in Q1 2024.
625 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2025.

Based on NorthRock Partners's 13F filing for Q2 2025, filed 25 Jul 2025.